U.S. Markets closed

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0200-0.0600 (-5.56%)
At close: 4:00PM EDT
1.0100 -0.01 (-0.98%)
After hours: 07:47PM EDT

Soligenix, Inc.

29 Emmons Drive
Suite B-10
Princeton, NJ 08540
United States
609 538 8200
http://www.soligenix.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher J. Schaber Ph.D.Chairman, CEO & Pres810.3kN/A1966
Mr. Jonathan L. Guarino CPA, CGMASr. VP, CFO & Corp. Sec.294.08kN/A1973
Dr. Oreola Donini Ph.D.Sr. VP & Chief Scientific Officer380.46kN/A1972
Dr. Richard C. Straube M.D., MSc.Sr. VP & Chief Medical Officer294.51kN/A1952
Mr. Richard L. DunningExec. OfficerN/AN/A1946
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which has completed Phase I/II clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Corporate Governance

Soligenix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.